Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Polynovo ( (AU:PNV) ).
PolyNovo Limited announced a change in the director’s interest, with Mr. Leon Hoare acquiring an additional 20,000 ordinary fully paid shares through his personal super account. This transaction, executed via an on-market trade, reflects a continued commitment by the director to the company’s growth and stability, potentially signaling confidence in PolyNovo’s future prospects to stakeholders.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited operates in the medical technology industry, specializing in the development and commercialization of innovative medical devices. The company’s primary focus is on products that aid in tissue repair and regeneration, particularly through its NovoSorb technology, which is used in various surgical and wound care applications.
Average Trading Volume: 2,686,764
Technical Sentiment Signal: Sell
Current Market Cap: A$1.02B
See more insights into PNV stock on TipRanks’ Stock Analysis page.